(266 days)
Not Found
Yes
The summary explicitly mentions and evaluates an "AI Denoising feature" and refers to "AI denoising" in the context of image processing and performance studies.
No.
The device is intended to produce images for diagnostic support, not for active treatment or therapy.
Yes
The "Intended Use / Indications for Use" section explicitly states that the system is intended to produce images "as diagnostic support." Furthermore, the "Device Description" details its function in producing 2D and 3D X-ray images of various anatomical regions, which are inherently used for diagnostic purposes.
No
The device description explicitly states it is an "X-ray unit" that uses "cone beam computed tomography (CBCT)" and produces 2D and 3D images. It also mentions "dedicated 3D reconstruction hardware." This indicates the device includes significant hardware components beyond just software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to perform tests on samples taken from the human body, such as blood, urine, or tissue, to provide information about a person's health.
- Device Function: The Planmeca Viso system produces images (2D and 3D X-ray and optical) of anatomical regions. It does not perform tests on biological samples.
- Intended Use: The intended use is to provide diagnostic support through imaging, not through analysis of biological specimens.
The device is an imaging system used for diagnostic purposes, but it falls under the category of medical imaging devices, not In Vitro Diagnostics.
No
The provided text does not contain any explicit statement that the FDA has reviewed, approved, or cleared a PCCP for this specific device.
Intended Use / Indications for Use
Planmeca Viso is a system intended to produce two-dimensional (2D) and three-dimensional (3D) digital X-ray images as well as three-dimensional (3D) optical images of the dento-maxillo-facial, cervical spine and ENT (Ear, Nose, and Throat) regions at the direction of healthcare professionals as diagnostic support for pediatric and adult patients.
Product codes (comma separated list FDA assigned to the subject device)
OAS
Device Description
The Planmeca Viso -X-ray unit uses cone beam computed tomography (CBCT) to produce three-dimensional (3D) images of the maxillofacial and ENT anatomies. Two dimensional (2D) images are produced with tomosynthesis method (panoramic) imaging) as well as conventional 2D radiography (cephalometric imaging, 2D views). In CBCT a cylindrical volume of data is captured in one imaging procedure. The data consists of several hundred sample images which are taken from different directions to cover a certain pre-programmed target area. These samples are used for 3D reconstruction (using a dedicated 3D reconstruction hardware) that can be viewed in three dimensions using separate workstation and Planmeca Romexis software.
Mentions image processing
AI Denoising feature of the endodontic image processing has been evaluated based on its ability to produce diagnostic image quality in its intended application.
Mentions AI, DNN, or ML
AI Denoising feature of the endodontic image processing has been evaluated based on its ability to produce diagnostic image quality in its intended application.
Input Imaging Modality
Computed Tomography X-ray System (CBCT), 2D radiography (panoramic and cephalometric imaging), 3D optical images.
Anatomical Site
dento-maxillo-facial, cervical spine and ENT (Ear, Nose, and Throat) regions
Indicated Patient Age Range
pediatric and adult patients
Intended User / Care Setting
healthcare professionals
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
AI Denoising feature of the endodontic image processing has been evaluated based on its ability to produce diagnostic image quality in its intended application. This was evaluated in a study performed by three dental professionals in a study conducted with eleven patients, by comparing images with no denoising and AI denoising.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
- Biocompatibility testing: No changes in patient contact parts compared to primary predicate device.
- Electrical safety and electromagnetic compatibility (EMC): CB and EMC testing was conducted as per IEC standards 60601-1+A1:2012+A2:2020, 60601-1-2+A1:2020, 60601-1-3+A1:2013+A2:2021, 60601-1-6+A1:2013+A2:2020, 60601-2-63+A1:2017+A2:2021,62366-1+A1:2020 and 62304+A1:2015
- Software Verification and Validation Testing: Performed as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance of Premarket Submissions for Software Contained in Medical Devices.". No issues identified.
- Bench testing: Performance testing in laboratory environment was performed with Viso (primary predicate device) and Viso (subject device) of the Sedentex and DIN 6868 Phantoms. The data was compared in order to see that the performance of the device remains substantially similar to that of the primary predicate device.
- Clinical evaluation: The main measure of clinical performance for Planmeca Viso is determined to be image quality. This has been evaluated by the product relevant team of professionals who evaluated human phantom images which were determined to be suitable for the intended purpose and indications for use of the device. These results are substantially equivalent to the evaluation performed on primary predicate device. AI Denoising feature of the endodontic image processing has been evaluated based on its ability to produce diagnostic image quality in its intended application. This was evaluated in a study performed by three dental professionals in a study conducted with eleven patients, by comparing images with no denoising and AI denoising.
- Testing summary: The above testing confirms that Planmeca Viso is safe and effective in its intended use.
- Conclusions: The performance data of the subject device and the predicate device is equal or close to equal. The performance testing provides data to back this similarity in the devices. The subject device performs equally or better in all the testing scenarios.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.1750 Computed tomography x-ray system.
(a)
Identification. A computed tomography x-ray system is a diagnostic x-ray system intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data from the same axial plane taken at different angles. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.
0
December 28, 2023
Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, with the word "ADMINISTRATION" underneath.
Planmeca Oy Niina Vuorikallas Director, Quality & Regulatory Affairs Asentajankatu 6 Helsinki. 00880 Finland
Re: K230985
Trade/Device Name: Planmeca Viso Regulation Number: 21 CFR 892.1750 Regulation Name: Computed Tomography X-Ray System Regulatory Class: Class II Product Code: OAS Dated: October 17, 2023 Received: November 3, 2023
Dear Niina Vuorikallas:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
1
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Gabriela M. Rodal Digitally signed by for Gabriela M. Rodal -S -2
Lu Jiang, Ph.D. Assistant Director DHT8B: Division of Radiologic Imaging Devices and Electronic Products OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
Submission Number (if known)
Device Name
Planmeca Viso
Indications for Use (Describe)
Planmeca Viso is a system intended to produce two-dimensional (2D) and three-dimensional (3D) digital X-ray images as well as three-dimensional (3D) optical images of the dento-maxillo-facial, cervical spine and ENT (Ear, Nose, and Throat) regions at the direction of healthcare professionals as diagnostic support for pediatric and adult patients.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW."
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
I. SUBMITTER
Manufacturer
Planmeca Oy Asentajankatu 6 00880 Helsinki, Finland Phone: +358 20 7795 500 Fax: +358 20 7795 555 Contact person: Niina Vuorikallas
U.S. designated agent
Planmeca U.S.A. Inc. 2600 Forbs Ave. Hoffman Est, IL 60192 UNITED STATES Contact person: Glen Kendrick
Date Prepared: December 27, 2023
II. DEVICE
| Name of Device: | Planmeca Viso |
|---|---|
| Common or Usual Name: | Computed Tomography X-ray System |
| Classification Name: | Computed Tomography X-ray System (CT) (21 CFR |
| 892.1750) | |
| Regulatory Class: | II |
| Product Code: | OAS |
III. PREDICATE DEVICE
Primary predicate device, #1, Planmeca Viso, Computed Tomography System 510(k): K181576 Regulation number: 892.1750 Regulatory Class: II Product Code: OAS
Predicate device #2, HDX DENTRIα. Computed Tomography System 510(k): K160140 Regulation number: 892.1750 Regulatory Class: II Product Code: OAS
Predicate device #3, DigiX FDX, Stationary X-ray system 510(k): K223060 Regulation number: 892.1680 Regulatory Class: II Product Code: KPR
4
Predicate device #2 is only used for X-ray tube comparison. Outside of figure 1, when referred to predicate device, the reference is made to primary predicate device, #1.
DEVICE DESCRIPTION IV.
The Planmeca Viso -X-ray unit uses cone beam computed tomography (CBCT) to produce three-dimensional (3D) images of the maxillofacial and ENT anatomies. Two dimensional (2D) images are produced with tomosynthesis method (panoramic) imaging) as well as conventional 2D radiography (cephalometric imaging, 2D views). In CBCT a cylindrical volume of data is captured in one imaging procedure. The data consists of several hundred sample images which are taken from different directions to cover a certain pre-programmed target area. These samples are used for 3D reconstruction (using a dedicated 3D reconstruction hardware) that can be viewed in three dimensions using separate workstation and Planmeca Romexis software.
INDICATIONS FOR USE V.
Same as predicate device.
Planmeca Viso is a system intended to produce two-dimensional (2D) and three-dimensional (3D) digital x-ray images as well as three-dimensional (3D) optical images of the dentomaxillo-facial, cervical spine and ENT (Ear, Nose, and Throat) regions at the direction of healthcare professionals as diagnostic support for pediatric and adult patients.
VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE
General
Both devices are 3D CBCT imaging system indicated for imaging dento-maxillofacial-. cervical spine- and ENT-regions and offer a variety of 3D fields of view suitable for each application.
Both systems also provide 2D imaging capabilities for panoramic and cephalometric imaging. In general there are only a few changes in the device.
Integrated detector
The X-ray detectors used are of same size as previously. Viso G5 and ProCeph use new X-ray detectors with similar qualities as the predicate device. Only difference between Viso G7 predicate and subject devices is the interface. Predicate device uses proprietary interface, and subject device uses standard ethernet interface. This has some effects on the device hardware, namely the grabber PCB, which is being replaced with a commercial Nvidia Jetson Nano module and suitable interface PCB. Otherwise they are of similar qualities as before and the produced 3D images provide similar diagnostic value. See fig 2 for technical comparison between devices.
X-ray unit
The dimensions and materials are identical to the predicate device.
X-ray tube
A new x-ray tube has been introduced to the device. It is of similar quality as predicate devices' fixed anode x-ray tubes, and it has maximum tube voltage of 120kV. Previously used fixed anode x-ray tubes may also be used with this device. No other changes for the tube head. Predicate device #2 operates a similar tube manufactured by the same company, the only difference being the target angle and thus the heat characteristics. See fig 1 for technical comparison on X-ray tube properties.
fig 1. X-ray tube comparison
5
| | Subject device | Primary predicate
device, #1 | Predicate device #2 |
|--------------------------------------------|----------------------------|---------------------------------|----------------------------|
| Tube type | OPX/105-10 | SXR 130-10-0.5 SC | OPX/105 |
| Nominal voltage | 120 kV | 130 kV | 110 kV |
| Focal spot | 0.5 mm | 0.5 mm | 0.5mm |
| Filament characteristics | 3.5 ÷ 6.0 V
2.5 ÷ 4.0 A | N/A | 3.5 ÷ 6.0 V
2.5 ÷ 4.0 A |
| Anode material | Tungsten | Tungsten | Tungsten |
| Target angle | 10° | 10° | 5° |
| Anode heat storage
capacity | 40000 J | 31500 J | 30000 J |
| Maximum anode cooling
rate | 500 W | 310 W | 250 W |
| Nominal anode input
power at 0.1 s (DC) | 1900 W | N/A | 2000 W |
| Inherent filtration | 0.5 mm Al | 1.1 mm Al | 0.5 mm Al |
X-ray generator
The device uses the same x-ray generator as before.
X-ray collimator
The device uses the same x-ray collimator as before.
Software
Software changes made to accommodate new hardware (see integrated detectors and new xray tube).
CT reconstruction algorithm
Device uses same CT reconstruction algorithm as before, no significant changes are made to the algorithm.
| fig 2. technical comparison | ||
|---|---|---|
| Technical specification | Subject device | Primary predicate device, #1 |
| Classification | ||
| FDA product class | OAS, class II | OAS, class II |
| RoHS | 2011/65/EU | 2011/65/EU |
| IEC 60601-1 | Class I, type B | Class I, type B |
| CISPR 11 | Class B | Class B |
| IP Classification | IPX0 | IPX0 |
| Applied parts | ||
| (according to IEC 60601-1: 2012) | ||
| Patient supports | As shown in section Patient | |
| supports in user's manuals | As shown in section Patient | |
| supports in user's manuals | ||
| Patient handles | ||
| Generator | ||
| (according to IEC 60601-2-7: |
-
| | |
| | Resonant-mode, DSP-controlled, 80 - 160 kHz | Resonant-mode, DSP-controlled, 80 - 160 kHz |
| X-ray tube | | |
| | D-059SBR or SXR 130-10-0.5 SC or OPX 105-10 | D-059SBR or SXR 130-10-0.5 SC |
| Focal spot size
(according to IEC 60336: 2005) | | |
| | 0.5 x 0.5 mm | 0.5 x 0.5 mm |
| Filtration | | |
| 3D | Total 2.5 mm Al + 0.2mm / 0.5 mm Cu | Total 2.5 mm Al + 0.2mm / 0.5 mm Cu |
| Pan (SmartPan) / ProCeph | Total 2.5 mm Al | Total 2.5 mm Al |
| Tube housing front cover
quality equivalent filtration
(not included in the specified
total filtration) | 0.3 mm Al @ 70 kV / HVL 2.6 mm Al | 0.3 mm Al @ 70 kV / HVL 2.6 mm Al |
| Anode voltage | | |
| 3D | 80 - 120 kV ±5% | 80 - 120 kV ±5% |
| Pan (SmartPan) | 60 - 84 kV ±5% | 60 - 84 kV ±5% |
| ProCeph | 60 - 84 kV ±5% | 60 - 84 kV ±5% |
| Anode current | | |
| 3D | D-059SBR: 2-12.5 mA ±10%
SXR 130-10-0.5 SC: 2-16mA ±10%
OPX 105-10: 2-16mA ±10% | D-059SBR: 1-12.5 mA ±10%
SXR 130-10-0.5 SC: 1-16mA ±10% |
| Pan (SmartPan) | D-059SBR: 2-14 mA ±10%
SXR 130-10-0.5 SC: 2-16mA ±10%
OPX 105-10: 2-16mA ±10% | D-059SBR: 1-14 mA ±10%
SXR 130-10-0.5 SC: 1-16mA ±10% |
| ProCeph | D-059SBR: 14 mA ±10%
SXR 130-10-0.5 SC: 16mA ±10%
OPX 105-10: 14mA ±10% | D-059SBR: 14 mA ±10%
SXR 130-10-0.5 SC: 16mA ±10% |
| mAs range | | |
| | min. / max. as indicated ±(10% + 0.2 mAs) | min. / max. as indicated ±(10% + 0.2 mAs) |
| Dose range and accuracy | | |
| | Dose range min. / max. as indicated on system user interface
Accuracy of dosimetric indication (DAP, CTDI): ±40% | Dose range min. / max. as indicated on system user interface
Accuracy of dosimetric indication (DAP, CTDI): ±40% |
| Linearity of radiation output | | |
| | 51 % @ 1lp/mm | > 48 % @ 1lp/mm |
| 3D: | | |
| Panel type | Viso G5: Varex 1616Z
Viso G7: Varex 2530DX | Viso G5: Varex 1616PT
Viso G7: Varex 2530PX |
| Flat panel pixel size | Viso G5: 105 μm
Viso G7: 139 μm | Viso G5: 127 μm
Viso G7: 139 μm |
| Flat panel active surface | Viso G5: 161.3 x 161.3 (6.35 x 6.35
in.)
Viso G7: 247.7x 301.1 mm (9.75 x
11.85 in.) | Viso G5: 157.5 x 157.5 mm (6.20 x
6.20 in.)
Viso G7: 299.7x 246.3 mm (11.80
x 9.70 in.) |
| DQE (0) | Viso G5: 78 % (1x1)
Viso G7: 70 % (1x1) | Viso G5: 70 % (1x1)
Viso G7: 70 % (1x1) |
| MTF | Viso G5: > 59 % @ 1lp/mm (1x1)
Viso G7: > 48 % @ 1lp/mm (1x1) | Viso G5: > 48 % @ 1lp/mm (1x1)
Viso G7: > 50 % @ 1lp/mm (1x1) |
| Voxel sizes | 75 μm, 150 μm, 300 μm, 450 μm,
600 μm | 75 μm, 150 μm, 300 μm, 450 μm,
600 μm |
| Pan (SmartPan): | | |
| Panel type | Viso G5: Varex 1616Z
Viso G7: Varex 2530DX | Viso G5: Varex 1616PT
Viso G7: Varex 2530PX |
| Flat panel pixel size | Viso G5: 105 μm
Viso G7: 139 μm | Viso G5: 127 μm
Viso G7: 139 μm |
| Flat panel active surface | Viso G5: 8.4 x 161.3 mm (0.33 x
6.35 in.)
Viso G7: 8.9/17.8 x 166.8 mm
(0.35/0.7 x 6.57 in.) | 8 - 25 x 146 mm (0.31 - 0.98 x
5.74 in.) |
| Operating requirements for
ProFace program | | |
| Optimum colour temperature | Approx. 6500 Kelvin | Approx. 6500 Kelvin |
| Even and uniform lighting | | |
| No bright lights | | |
6
7
8
9
PERFORMANCE DATA VII.
The following performance data were provided in support of the substantial equivalence determination.
Biocompatibility testing
No changes in patient contact parts compared to primary predicate device. Electrical safety and electromagnetic compatibility (EMC)
10
CB and EMC testing was conducted as per IEC standards 60601-1+A1:2012+A2:2020, 60601-1-2+A1:2020, 60601-1-3+A1:2013+A2:2021, 60601-1-6+A1:2013+A2:2020, 60601-2-63+A1:2017+A2:2021,62366-1+A1:2020 and 62304+A1:2015
Software Verification and Validation Testing
Software verification and validation was performed as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance of Premarket Submissions for Software Contained in Medical Devices.". No issues have been identified during the verification and validation process.
Bench testing
Performance testing in laboratory environment was performed with Viso (primary predicate device) and Viso (subject device) of the Sedentex and DIN 6868 Phantoms. The data was compared in order to see that the performance of the device remains substantially similar to that of the primary predicate device.
Clinical evaluation
The main measure of clinical performance for Planmeca Viso is determined to be image quality. This has been evaluated by the product relevant team of professionals who evaluated human phantom images which were determined to be suitable for the intended purpose and indications for use of the device. These results are substantially equivalent to the evaluation performed on primary predicate device.
AI Denoising feature of the endodontic image processing has been evaluated based on its ability to produce diagnostic image quality in its intended application. This was evaluated in a study performed by three dental professionals in a study conducted with eleven patients, by comparing images with no denoising and AI denoising.
Testing summary
The above testing confirms that Planmeca Viso is safe and effective in its intended use.
VIII. CONCLUSIONS
The performance data of the subject device and the predicate device is equal or close to equal. The performance testing provides data to back this similarity in the devices. The subject device performs equally or better in all the testing scenarios.
The IGZO technology is proven to bring improvements in electronic noise, image lag and noise-equivalent quanta. The IGZO technology has been used in several FDA approved devices at least since 2019.
The tube specifications regarding eg. focus size, anode angle and tube voltage are the same as previously approved Canon D-059SB X-ray tube. The OPX 105-10 X-ray tube is driven with the same hardware as our other previously approved X-ray tubes.
The comparison of characteristics supports substantial equivalence. Planmeca Viso is as safe and effective as the predicate device.